Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.64
CYTK's Cash to Debt is ranked lower than
68% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. CYTK: 2.64 )
Ranked among companies with meaningful Cash to Debt only.
CYTK' s Cash to Debt Range Over the Past 10 Years
Min: 2.64  Med: 27.34 Max: No Debt
Current: 2.64
Equity to Asset 0.53
CYTK's Equity to Asset is ranked lower than
67% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CYTK: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
CYTK' s Equity to Asset Range Over the Past 10 Years
Min: -1.73  Med: 0.82 Max: 0.96
Current: 0.53
-1.73
0.96
Interest Coverage 0.25
CYTK's Interest Coverage is ranked lower than
100% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTK: 0.25 )
Ranked among companies with meaningful Interest Coverage only.
CYTK' s Interest Coverage Range Over the Past 10 Years
Min: 0.25  Med: No Debt Max: No Debt
Current: 0.25
F-Score: 3
Z-Score: 0.38
M-Score: 651.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 0.61
CYTK's Operating margin (%) is ranked higher than
71% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. CYTK: 0.61 )
Ranked among companies with meaningful Operating margin (%) only.
CYTK' s Operating margin (%) Range Over the Past 10 Years
Min: -1961.56  Med: -445.18 Max: 32
Current: 0.61
-1961.56
32
Net-margin (%) -1.70
CYTK's Net-margin (%) is ranked higher than
70% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. CYTK: -1.70 )
Ranked among companies with meaningful Net-margin (%) only.
CYTK' s Net-margin (%) Range Over the Past 10 Years
Min: -1912.57  Med: -406.42 Max: 30.1
Current: -1.7
-1912.57
30.1
ROE (%) -2.16
CYTK's ROE (%) is ranked higher than
74% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. CYTK: -2.16 )
Ranked among companies with meaningful ROE (%) only.
CYTK' s ROE (%) Range Over the Past 10 Years
Min: -85.46  Med: -55.74 Max: 32.47
Current: -2.16
-85.46
32.47
ROA (%) -1.18
CYTK's ROA (%) is ranked higher than
76% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. CYTK: -1.18 )
Ranked among companies with meaningful ROA (%) only.
CYTK' s ROA (%) Range Over the Past 10 Years
Min: -73.2  Med: -42.86 Max: 23.37
Current: -1.18
-73.2
23.37
ROC (Joel Greenblatt) (%) 7.88
CYTK's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. CYTK: 7.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3507.33  Med: -602.95 Max: 570.52
Current: 7.88
-3507.33
570.52
Revenue Growth (3Y)(%) 21.00
CYTK's Revenue Growth (3Y)(%) is ranked higher than
74% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CYTK: 21.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -39.2 Max: 154.5
Current: 21
0
154.5
EBITDA Growth (3Y)(%) -24.60
CYTK's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. CYTK: -24.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.6  Med: -24.6 Max: 2.5
Current: -24.6
-53.6
2.5
EPS Growth (3Y)(%) -25.00
CYTK's EPS Growth (3Y)(%) is ranked lower than
75% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. CYTK: -25.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55  Med: -25 Max: 8.1
Current: -25
-55
8.1
» CYTK's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CYTK Guru Trades in Q4 2015

Jim Simons 519,278 sh (+136.36%)
Paul Tudor Jones 27,672 sh (+41.24%)
Charles Brandes 18,300 sh (unchged)
» More
Q1 2016

CYTK Guru Trades in Q1 2016

Charles Brandes Sold Out
Paul Tudor Jones 15,008 sh (-45.76%)
Jim Simons 184,479 sh (-64.47%)
» More
Q2 2016

CYTK Guru Trades in Q2 2016

Paul Tudor Jones 16,470 sh (+9.74%)
Jim Simons Sold Out
» More
Q3 2016

CYTK Guru Trades in Q3 2016

Paul Tudor Jones 41,300 sh (+150.76%)
» More
» Details

Insider Trades

Latest Guru Trades with CYTK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CYNA, NAS:RVNC, NAS:XBIT, NAS:ASND, NAS:NERV, NAS:NSTG, NAS:SELB, NAS:CRIS, OTCPK:GNFTF, NAS:VSAR, NAS:MYOK, NAS:OMER, NAS:FLML, NAS:BLCM, NAS:OTIC, NAS:CLDX, NAS:EDIT, NAS:CLSD, NAS:INO, NAS:MCRB » details
Traded in other countries:KK3A.Germany,
Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Cytokinetics Inc was incorporated under the laws of the state of Delaware on August 5, 1997. The Company is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its research and development activities relating to the biology of muscle function have evolved from its knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Its advanced research and development programs relates to the biology of muscle function and are directed to small molecule modulators of the contractility of skeletal or cardiac muscle. It also conducts earlier-stage research directed to other compounds with the potential to modulate muscle contractility and other muscle functions, such as growth, energetics and metabolism. Its drug candidate from its skeletal muscle contractility program, tirasemtiv, formerly known as CK-2017357, is a fast skeletal muscle troponin activator. The Company's cardiac muscle contractility program is focused on the cardiac sarcomere, the basic unit of muscle contraction in the heart. Its drug candidate from this program, omecamtiv mecarbil, formerly known as CK-1827452, is a novel cardiac muscle myosin activator that is being developed under a strategic alliance with Amgen. It is conducting joint research with Amgen directed to next-generation compounds in its cardiac muscle contractility program. The Company is currently conducting a Phase II clinical trials program for tirasemtiv, including an ongoing Phase IIb clinical trial in patients with ALS, known as BENEFIT-ALS, Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS. It is also developing CK-2127107, a structurally distinct, fast skeletal muscle troponin activator, under a strategic alliance with Astellas. The Company competes with Mitsubishi Tanabe Pharma Corporation, Eisai Inc., Trophos SA, Neuraltus Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., GlaxoSmithKline plc., BrainStorm Cell Therapeutics and Neuralstem. The Company's research, testing, manufacturing, selling and marketing of drugs are subject to extensive regulation by the FDA and other regulatory authorities in the United States.

Ratios

vs
industry
vs
history
P/B 5.49
CYTK's P/B is ranked lower than
67% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CYTK: 5.49 )
Ranked among companies with meaningful P/B only.
CYTK' s P/B Range Over the Past 10 Years
Min: 0.89  Med: 2.33 Max: 9.96
Current: 5.49
0.89
9.96
P/S 5.73
CYTK's P/S is ranked higher than
68% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. CYTK: 5.73 )
Ranked among companies with meaningful P/S only.
CYTK' s P/S Range Over the Past 10 Years
Min: 1.84  Med: 13.03 Max: 95.5
Current: 5.73
1.84
95.5
EV-to-EBIT 530.48
CYTK's EV-to-EBIT is ranked lower than
98% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. CYTK: 530.48 )
Ranked among companies with meaningful EV-to-EBIT only.
CYTK' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.5  Med: -2 Max: 634.5
Current: 530.48
-18.5
634.5
EV-to-EBITDA 284.23
CYTK's EV-to-EBITDA is ranked lower than
96% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. CYTK: 284.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYTK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.1  Med: -2.05 Max: 339.9
Current: 284.23
-19.1
339.9
Current Ratio 5.05
CYTK's Current Ratio is ranked higher than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CYTK: 5.05 )
Ranked among companies with meaningful Current Ratio only.
CYTK' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 6.19 Max: 23.3
Current: 5.05
1.85
23.3
Quick Ratio 5.05
CYTK's Quick Ratio is ranked higher than
57% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. CYTK: 5.05 )
Ranked among companies with meaningful Quick Ratio only.
CYTK' s Quick Ratio Range Over the Past 10 Years
Min: 1.85  Med: 6.19 Max: 23.3
Current: 5.05
1.85
23.3
Days Sales Outstanding 294.54
CYTK's Days Sales Outstanding is ranked lower than
96% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. CYTK: 294.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.06  Med: 1.81 Max: 4910.75
Current: 294.54
0.06
4910.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.60
CYTK's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CYTK: -18.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -182.7  Med: -25.6 Max: -10.7
Current: -18.6
-182.7
-10.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 125.56
CYTK's Price/Net Cash is ranked lower than
97% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. CYTK: 125.56 )
Ranked among companies with meaningful Price/Net Cash only.
CYTK' s Price/Net Cash Range Over the Past 10 Years
Min: 0.99  Med: 3.22 Max: 126.44
Current: 125.56
0.99
126.44
Price/Net Current Asset Value 6.24
CYTK's Price/Net Current Asset Value is ranked lower than
54% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. CYTK: 6.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYTK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.96  Med: 3.04 Max: 9.59
Current: 6.24
0.96
9.59
Price/Tangible Book 5.49
CYTK's Price/Tangible Book is ranked lower than
59% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CYTK: 5.49 )
Ranked among companies with meaningful Price/Tangible Book only.
CYTK' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.95  Med: 2.57 Max: 7.73
Current: 5.49
0.95
7.73
Price/Median PS Value 0.44
CYTK's Price/Median PS Value is ranked higher than
84% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CYTK: 0.44 )
Ranked among companies with meaningful Price/Median PS Value only.
CYTK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 1.06 Max: 6.51
Current: 0.44
0.15
6.51
Earnings Yield (Greenblatt) (%) 0.21
CYTK's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CYTK: 0.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYTK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 34 Max: 3342.8
Current: 0.21
0.2
3342.8

More Statistics

Revenue (TTM) (Mil) $83.03
EPS (TTM) $ -0.10
Beta1.95
Short Percentage of Float7.39%
52-Week Range $6.00 - 12.98
Shares Outstanding (Mil)40.52

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 85 43 70
EPS ($) -0.37 -1.43 -1.13
EPS w/o NRI ($) -0.37 -1.43 -1.13
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CYTK

Headlines

Articles On GuruFocus.com
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Aug 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares Jun 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares May 20 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares May 14 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) May 07 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 28 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 01 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 05 2009 
Cytokinetics Inc. (CYTK) President & CEO Robert I Blum sells 1,000 Shares Aug 06 2009 

More From Other Websites
Cytokinetics, Inc. (CYTK) Hedge Funds Are Snapping Up Dec 09 2016
CYTOKINETICS INC Files SEC form 8-K, Other Events Dec 07 2016
7:31 am Cytokinetics: Origent data sciences and Cytokinetics present analyses demonstrating baseline... Dec 07 2016
Origent Data Sciences and Cytokinetics Present Analyses Demonstrating Baseline Data Predict Measures... Dec 07 2016
CYTOKINETICS INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 05 2016
Cytokinetics Announces Presentations at the International Symposium on ALS/MND Dec 02 2016
Cytokinetics Gets $27M Milestone from Amgen (AMGN, CYTK) Dec 01 2016
The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved... Dec 01 2016
Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil Dec 01 2016
CYTOKINETICS INC Files SEC form 8-K, Other Events Dec 01 2016
Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil Dec 01 2016
The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved... Nov 30 2016
The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved... Nov 30 2016
CYTOKINETICS INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 23 2016
Cytokinetics to Participate in Upcoming Investor Conferences Nov 22 2016
Cytokinetics to Participate in Upcoming Investor Conferences Nov 22 2016
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the AHA Annual... Nov 14 2016
Surging Earnings Estimates Signal Good News for Cytokinetics (CYTK) Nov 14 2016
CYTOKINETICS INC Financials Nov 10 2016
Cytokinetics Announces New Results From COSMIC-HF to be Presented at the American Heart Association... Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)